Veterinary API Market Size
The Global Veterinary API Market reached US$ 7.92 billion in 2025 and is expected to reach US$ 16.47 billion by 2035 growing with a CAGR of 7.6% during the forecast period 2026-2035.
A veterinary active pharmaceutical ingredient (veterinary API) refers to the active substance in a pharmaceutical product designed for animal health. It is the primary component responsible for delivering the desired therapeutic effect in animals. Veterinary APIs are crucial for the formulation and production of medications aimed at treating, preventing, or managing a range of diseases and health conditions in animals.
Veterinary Active Pharmaceutical Ingredients (APIs) are essential components of finished pharmaceutical products, serving as the primary ingredients in these formulations. Most APIs are derived from chemical synthesis, biotechnological processes, or the extraction of natural substances by raw material manufacturers. Veterinary APIs are the foundational chemicals used in the production of final drug products, and the quality of these finished veterinary medications is directly influenced by the quality of the APIs used.
Veterinary API Market Key Takeaways
- Market scale: The Veterinary API Market is valued at US$ 7.92 billion in 2025 and is projected to reach US$ 16.47 billion by 2035 at a 7.6% CAGR.
- Vaccines remain the leading API type: Vaccines represented approximately 56.5% of the global market share, supported by animal disease prevention and livestock health requirements.
- Pet healthcare is expanding the addressable demand base: Rising pet ownership is increasing demand for veterinary medicines, advanced care, surgical procedures, and APIs.
- North America leads the market: The region benefits from established veterinary healthcare infrastructure, pet ownership, demand for animal-derived food products, and attention to zoonotic diseases.
- Asia-Pacific offers faster expansion: The region is identified as the fastest-growing market, supported by animal healthcare needs, livestock populations, manufacturing capabilities, and increasing veterinary pharmaceutical activity.
- Manufacturing partnerships are becoming commercially important: Contract manufacturing agreements and API outsourcing provide animal health companies with access to production capabilities while supporting supplier revenue growth.
- Vaccine capacity is attracting investment: New manufacturing facilities and vaccine initiatives demonstrate the importance of production scale and supply security in animal health pharmaceuticals.
Veterinary API Market Scope
| Metric | Details |
| Market Size in 2025 | US$ 7.92 billion |
| Market Size by 2035 | US$ 16.47 billion |
| CAGR | 7.60% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | API Type, Synthesis Type, Route of Administration, Animal Type, Service Type, and Region |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
For more details on this report - Request for Sample
Veterinary API Market Dynamics: Drivers
Increasing animal population and pet ownership
The demand for the global veterinary API market is driven by multiple factors. One of the primary factors is the increasing animal population & pet ownership. The growing animal population has led to an increase in demand for surgical procedures, including orthopedic, neurosurgical, and cardiovascular surgeries. All these factors driving the veterinary API market.
The rising number of pets has led to an increase in the adoption of advanced veterinary API drugs. The overall population of pet dogs in India was over 33 million in 2023. The population is likely to reach more than 51 million by 2028. According to the global state of pet care stats, in September 2022, a growing pet population means a greater need for veterinary care and veterinary API drugs to cure pet care requirements.
Moreover, the growing pet ownership trend is driving the demand for veterinary care, including surgical procedures. As more people treat their pets as family members, they are willing to invest in high-quality veterinary care, including advanced surgical procedures and invest more in veterinary API drugs to provide better treatment for veterinary health.
Moreover, key players in the industry have innovative launches and technological advancements in veterinary healthcare that would drive this market growth. For instance, in December 2023, eVerse.AI introduced CowGPT, the first Generative AI application specifically designed for the dairy and animal care sectors. This innovative tool has generated significant interest in the industry, which has been rapidly evolving due to advancements in Generative AI over the past year.
The company is also in talks with the National Dairy Development Board (NDDB) in India to establish an API-based integration with the ConnectedCow platform and the INAPH/NDLM systems. Once this integration is completed, it could potentially provide access to data on over 250 million animals through the ConnectedCow platform.
Similarly, in June 2021, Lasa Supergenerics Limited, a leader in the production of Veterinary and Human APIs in India, expanded its product range by introducing Oxyclozanide. This addition leverages the company's expertise in catalyst chemistry and its fully integrated manufacturing capabilities.
Oxyclozanide is an anthelmintic used for treating fascioliasis, a type of worm infection primarily affecting livestock such as cattle, sheep, and goats. The company plans to initiate production at its Chiplun facility in August 2021, aiming to serve both domestic and international markets.
Restraints
Factors such as the high cost of animal care, lack of awareness, difficulties in the synthesis of large molecular weight API synthesis, limited approved animal therapies, increasing costs for veterinary research, and stringent government regulations, are expected to hamper the market.
Veterinary API Market Segment Analysis
The global veterinary API market is segmented based on API type, synthesis type, route of administration, animal type, service type, and region.
The vaccines segment accounted for approximately 56.5% of the global veterinary API market share
The vaccines segment is expected to hold the largest market share over the forecast period. The growing prevalence of chronic diseases in animals is leading to a demand for vaccines. This need is further driven by rising livestock populations and the commercialization of animal products, which necessitate effective disease management strategies.
Vaccines such as those for rabies, equine influenza, and foot-and-mouth disease are widely administered to inhibit the transmission of infectious pathogens by mimicking naturally acquired immunity. The effectiveness of these vaccines contributes to the high demand for veterinary vaccines in the market.
Moreover, key players in the industry invested in veterinary healthcare and introduced innovative vaccines that would drive this segment's growth in this market. For instance, in December 2023, Indian Immunologicals Limited (IIL) commenced construction of a Rs. 700 crore state-of-the-art veterinary vaccine facility in Genome Valley, Hyderabad. This greenfield project is aimed at enhancing India's vaccine security against economically important diseases like Foot and Mouth Disease (FMD) and other emerging threats.
Similarly, in June 2023, Boehringer Ingelheim Animal Health Canada Inc. introduced a new vaccine combination that protects two of the most serious and economically impactful swine diseases in a single dose. Utilizing a proprietary purification process, Boehringer Ingelheim has successfully combined its Ingelvac CircoFLEX with the leading Ingelvac PRRS MLV vaccine without compromising the effectiveness of PRRS protection. This innovative vaccine combination offers veterinarians and producers greater flexibility in selecting the most suitable vaccine for their herd and disease management strategies.
In addition, major players in the industry more focus on the key developments in veterinary vaccines helps to drive this market growth. For instance, in January 2023, Merck Animal Health, announced the opening of a state-of-the-art manufacturing facility in Boxmeer, the Netherlands, for sterile filling and freeze drying of companion animal vaccines.
Boxmeer is one of the company's centers for the development and production of veterinary vaccines, and the location is part of a manufacturing network in the Netherlands that includes existing production and research facilities in Boxmeer and De Bilt. The new facility will provide Merck Animal Health with additional manufacturing resources to meet the growing customer demand for its innovative vaccines.
Veterinary API Market Geographical Share
North America accounted for approximately XX% of the global veterinary API market share.
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of zoonotic diseases, growing demand for animal-derived food products, and well-established veterinary healthcare infrastructure helping to drive this market growth in the region.
Moreover, in this region, rising pet population & ownership, key player strategies such as partnerships & collaborations, and government support would propel this market growth. For instance, in November 2022, Dutch, a virtual veterinary care provider, partnered with Synchrony, a consumer financial services company, to offer Pets Best insurance to its annual veterinary care members.
According to NAPHIA despite over 90.5 million American families owning pets, only 3% of U.S. pets are insured. Dutch aims to address this gap by providing easy access to common veterinary needs through telemedicine, personalized treatment plans, and prescription fulfillment in most states.
Dutch and Pets Best are leveraging API-driven solutions and innovative pet insurance products to meet the growing demand for veterinary services, further advancing the pet health industry. The accident-only policies exclude pre-existing injuries, cruciate ligament injuries, and any illnesses or diseases, including infectious bacterial or viral diseases, parasitic infections, metabolic disorders, or cancer.
Similarly, in August 2023, Dômes Pharma announced the successful acquisition of SentrX Animal Care. SentrX specializes in developing and manufacturing ophthalmology products utilizing its proprietary BioHAnce technology. This patented technology involves crosslinked Hyaluronic Acid, which enhances and accelerates natural healing, hydration, and lubrication while minimizing the frequency of applications required.
Veterinary API Market Segmentation
By API Type
- Anti-infectives
- Vaccines
- NSAIDs
- Antiparasitics
- Others
By Synthesis Type
- Chemical Based API
- Biological API
- Highly Potent API (HPAPI)
By Route of Administration
- Oral
- Injectable
- Topical
By Animal Type
- Companion Animals
- Production Animals
By Service Type
- In House
- Contract Outsourcing
- Contract Development
- Contract Manufacturing
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- The rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Veterinary API Market Competitive Landscape
The major global players in the veterinary API market include SUANFARMA, Alivira Animal Health Limited, Zoetis, Excel Industries, Sidhiv Pharma, Chempro Pharma Private Limited, De Ofichem Group, NGL Fine-Cheam Ltd., AMGIS Lifescience Ltd., and Rochem International Inc. among others.
Veterinary API Market Key Developments
September 2026: In the United States, the FDA Center for Veterinary Medicine launched a pilot program encouraging domestic manufacturing of veterinary drug products and active ingredients, with priority-review considerations for applications using U.S.-manufactured APIs. Key themes include supply-chain resilience, API security, domestic sourcing, and shortage prevention.
September 2026: In India, pharmaceutical manufacturers continued expanding capabilities in complex APIs, specialized molecules, advanced manufacturing, and regulated-market supply, supporting the country's growing role in global pharmaceutical and veterinary API supply chains.
August 2026: In North America and Europe, veterinary pharmaceutical development increasingly emphasized high-quality APIs, GMP manufacturing, antimicrobial stewardship, regulatory compliance, and reliable sourcing.
July 2026: In Asia-Pacific, veterinary API suppliers continued strengthening chemical synthesis, biological APIs, contract manufacturing, analytical testing, and R&D capabilities, supported by expanding livestock and companion-animal healthcare requirements.
June 2026: In the United States, FDA's MUMS Blueprint 2026–2028 highlighted opportunities to expand drug development for minor animal species and underserved veterinary conditions, encouraging innovation across veterinary pharmaceutical and API supply chains.
June 2026: In Europe, veterinary medicine development continued focusing on new active substances, antimicrobial therapies, antiparasitic treatments, companion-animal medicines, and regulatory harmonization.
May 2026: In Europe, the EMA's veterinary medicines committee advanced pharmaceutical development, regulatory guidance, pharmacovigilance, and international harmonization, including implementation of VICH pharmaceutical-development guidelines.
April 2026: Globally, veterinary API manufacturers increasingly prioritized quality-by-design, process optimization, regulatory documentation, traceability, antimicrobial-resistance management, and diversified sourcing.
Why Purchase the Report?
- To visualize the global veterinary API market segmentation based on API type, synthesis type, route of administration, animal type, service type, and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous veterinary API market data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The global veterinary API market report would provide approximately 78 tables, 74 figures, and 184 pages.
Target Audience
- Veterinary API manufacturers and pharmaceutical companies
- Animal health product manufacturers and buyers
- Contract development and contract manufacturing organizations
- Veterinary pharmaceutical suppliers
- Companion animal healthcare companies
- Livestock and production animal healthcare companies
- Industry investors and investment bankers
- Pharmaceutical procurement and sourcing teams
- Business development and corporate strategy teams
- Research and development professionals
- Emerging animal health and API companies
- Regulatory and quality professionals
Veterinary API Market Report Benefits
The report provides a structured assessment of the Veterinary API Market across API type, synthesis type, route of administration, animal type, service type, and region. It enables stakeholders to evaluate market size, growth prospects, demand patterns, competitive positioning, company strategies, product developments, pricing considerations, regulatory factors, and supply-chain dynamics.
The report also provides an Excel data sheet containing numerous market data points across the covered segments, along with product mapping of key products offered by major players. The source report comprises approximately 78 tables, 74 figures, and 184 pages, supporting detailed analysis for commercial planning and investment assessment.
Conclusion
The Veterinary API Market presents a sustained growth opportunity as animal healthcare becomes more important across companion animals and livestock. The market expands from US$ 7.92 billion in 2025 to US$ 16.47 billion by 2035, creating a substantial addressable opportunity for API producers, veterinary pharmaceutical companies, and contract manufacturing partners.
Vaccines remain the most significant API category, accounting for 56.5% of market share, while North America maintains the leading regional position and Asia-Pacific offers the fastest growth trajectory. Manufacturing investment, veterinary vaccine capacity, specialized API portfolios, and outsourcing agreements point to an industry where production capability and supply reliability will increasingly influence competitive performance.
The commercial question for market participants is therefore not simply how much veterinary pharmaceutical demand will grow, but where API capacity, specialized products, and manufacturing partnerships can capture that demand most effectively. Companies with strong quality systems, diversified portfolios, regional manufacturing access, and the ability to meet evolving veterinary healthcare requirements are positioned to compete for the market opportunity through 2035.
